vs
CREATIVE REALITIES, INC.（CREX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是CREATIVE REALITIES, INC.的1.3倍（$30.3M vs $23.9M），CREATIVE REALITIES, INC.净利率更高（-8.2% vs -221.3%，领先213.1%），CREATIVE REALITIES, INC.同比增速更快（117.2% vs 43.0%），CREATIVE REALITIES, INC.自由现金流更多（$-4.6M vs $-52.8M），过去两年CREATIVE REALITIES, INC.的营收复合增速更高（39.5% vs 39.4%）
Creative Realities, Inc.是一家端到端沉浸式数字体验解决方案提供商，主营互动数字标牌、内容管理软件及定制体验设计服务，主要面向北美零售、酒店、医疗、企业办公及公共领域客户，助力品牌提升客户参与度与运营效率。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CREX vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.9M
营收增速更快
CREX
高出74.2%
43.0%
净利率更高
CREX
高出213.1%
-221.3%
自由现金流更多
CREX
多$48.2M
$-52.8M
两年增速更快
CREX
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.9M | $30.3M |
| 净利润 | $-2.0M | $-67.1M |
| 毛利率 | 47.9% | — |
| 营业利润率 | 1.9% | -190.0% |
| 净利率 | -8.2% | -221.3% |
| 营收同比 | 117.2% | 43.0% |
| 净利润同比 | 30.8% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CREXRGNX
| Q4 25 | $23.9M | $30.3M | ||
| Q3 25 | $10.5M | $29.7M | ||
| Q2 25 | $13.0M | $21.4M | ||
| Q1 25 | $9.7M | $89.0M | ||
| Q4 24 | $11.0M | $21.2M | ||
| Q3 24 | $14.4M | $24.2M | ||
| Q2 24 | $13.1M | $22.3M | ||
| Q1 24 | $12.3M | $15.6M |
净利润CREXRGNX
| Q4 25 | $-2.0M | $-67.1M | ||
| Q3 25 | $-7.9M | $-61.9M | ||
| Q2 25 | $-1.8M | $-70.9M | ||
| Q1 25 | $3.4M | $6.1M | ||
| Q4 24 | $-2.8M | $-51.2M | ||
| Q3 24 | $54.0K | $-59.6M | ||
| Q2 24 | $-615.0K | $-53.0M | ||
| Q1 24 | $-109.0K | $-63.3M |
毛利率CREXRGNX
| Q4 25 | 47.9% | — | ||
| Q3 25 | 45.3% | — | ||
| Q2 25 | 38.5% | — | ||
| Q1 25 | 45.7% | — | ||
| Q4 24 | 44.2% | 70.2% | ||
| Q3 24 | 45.6% | 48.8% | ||
| Q2 24 | 51.8% | 52.5% | ||
| Q1 24 | 46.9% | 72.6% |
营业利润率CREXRGNX
| Q4 25 | 1.9% | -190.0% | ||
| Q3 25 | -68.9% | -176.3% | ||
| Q2 25 | -10.2% | -296.3% | ||
| Q1 25 | -7.4% | 13.6% | ||
| Q4 24 | -6.5% | -242.1% | ||
| Q3 24 | 7.9% | -256.6% | ||
| Q2 24 | 4.5% | -251.3% | ||
| Q1 24 | -0.6% | -408.8% |
净利率CREXRGNX
| Q4 25 | -8.2% | -221.3% | ||
| Q3 25 | -74.5% | -208.3% | ||
| Q2 25 | -13.9% | -331.8% | ||
| Q1 25 | 34.6% | 6.8% | ||
| Q4 24 | -25.8% | -241.3% | ||
| Q3 24 | 0.4% | -246.3% | ||
| Q2 24 | -4.7% | -237.7% | ||
| Q1 24 | -0.9% | -405.4% |
每股收益（稀释后）CREXRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | $-0.75 | $-1.20 | ||
| Q2 25 | $-0.17 | $-1.38 | ||
| Q1 25 | $0.32 | $0.12 | ||
| Q4 24 | $-0.28 | $-0.99 | ||
| Q3 24 | $0.01 | $-1.17 | ||
| Q2 24 | $-0.06 | $-1.05 | ||
| Q1 24 | $-0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $230.1M |
| 总债务越低越好 | $44.0M | — |
| 股东权益账面价值 | $21.5M | $102.7M |
| 总资产 | $151.0M | $453.0M |
| 负债/权益比越低杠杆越低 | 2.04× | — |
8季度趋势，按日历期对齐
现金及短期投资CREXRGNX
| Q4 25 | $1.6M | $230.1M | ||
| Q3 25 | $314.0K | $274.2M | ||
| Q2 25 | $569.0K | $323.3M | ||
| Q1 25 | $1.1M | $267.9M | ||
| Q4 24 | $1.0M | $234.7M | ||
| Q3 24 | $868.0K | $255.5M | ||
| Q2 24 | $4.1M | $290.4M | ||
| Q1 24 | $2.9M | $338.7M |
总债务CREXRGNX
| Q4 25 | $44.0M | — | ||
| Q3 25 | $22.0M | — | ||
| Q2 25 | $19.9M | — | ||
| Q1 25 | $23.0M | — | ||
| Q4 24 | $13.0M | — | ||
| Q3 24 | $10.7M | — | ||
| Q2 24 | $13.6M | — | ||
| Q1 24 | $12.8M | — |
股东权益CREXRGNX
| Q4 25 | $21.5M | $102.7M | ||
| Q3 25 | $21.9M | $161.5M | ||
| Q2 25 | $29.4M | $213.7M | ||
| Q1 25 | $29.9M | $274.2M | ||
| Q4 24 | $25.5M | $259.7M | ||
| Q3 24 | $28.3M | $301.4M | ||
| Q2 24 | $28.2M | $348.3M | ||
| Q1 24 | $28.8M | $390.7M |
总资产CREXRGNX
| Q4 25 | $151.0M | $453.0M | ||
| Q3 25 | $61.3M | $525.2M | ||
| Q2 25 | $63.7M | $581.0M | ||
| Q1 25 | $67.0M | $490.9M | ||
| Q4 24 | $65.2M | $466.0M | ||
| Q3 24 | $67.6M | $519.1M | ||
| Q2 24 | $69.6M | $569.4M | ||
| Q1 24 | $68.2M | $629.2M |
负债/权益比CREXRGNX
| Q4 25 | 2.04× | — | ||
| Q3 25 | 1.00× | — | ||
| Q2 25 | 0.68× | — | ||
| Q1 25 | 0.77× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | 0.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-4.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | -19.1% | -174.0% |
| 资本支出强度资本支出/营收 | 0.4% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CREXRGNX
| Q4 25 | $-4.5M | $-52.3M | ||
| Q3 25 | $-1.6M | $-56.0M | ||
| Q2 25 | $773.0K | $-49.3M | ||
| Q1 25 | $-2.4M | $33.6M | ||
| Q4 24 | $-1.4M | $-31.6M | ||
| Q3 24 | $544.0K | $-40.5M | ||
| Q2 24 | $2.3M | $-45.5M | ||
| Q1 24 | $1.9M | $-55.5M |
自由现金流CREXRGNX
| Q4 25 | $-4.6M | $-52.8M | ||
| Q3 25 | $-1.7M | $-56.5M | ||
| Q2 25 | $672.0K | $-49.7M | ||
| Q1 25 | $-2.5M | $32.6M | ||
| Q4 24 | $-1.4M | $-32.7M | ||
| Q3 24 | $543.0K | $-40.9M | ||
| Q2 24 | $2.3M | $-46.0M | ||
| Q1 24 | $1.9M | $-56.0M |
自由现金流率CREXRGNX
| Q4 25 | -19.1% | -174.0% | ||
| Q3 25 | -16.2% | -189.9% | ||
| Q2 25 | 5.2% | -232.8% | ||
| Q1 25 | -25.2% | 36.6% | ||
| Q4 24 | -12.5% | -154.2% | ||
| Q3 24 | 3.8% | -168.9% | ||
| Q2 24 | 17.3% | -206.2% | ||
| Q1 24 | 15.7% | -358.5% |
资本支出强度CREXRGNX
| Q4 25 | 0.4% | 1.7% | ||
| Q3 25 | 1.0% | 1.7% | ||
| Q2 25 | 0.8% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.0% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率CREXRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.73× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.07× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CREX
| Service And Other | $17.3M | 72% |
| Managed Services | $4.7M | 20% |
| Installation Services | $1.7M | 7% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
